155 related articles for article (PubMed ID: 24720120)
1. [Pharmacotherapy of atopic eczema--an analysis of the discrepancies between recent expert guidelines, official drug licenses, and evidence for efficacy of recommended drugs].
Kordus K; Spiewak R
Przegl Lek; 2013; 70(12):1021-6. PubMed ID: 24720120
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacotherapy of allergic contact dermatitis in the time of hegemony of the Summary of Product Characteristics].
Kordus K; Plichta D; Spiewak R
Pol Merkur Lekarski; 2013 Jan; 34(199):18-23. PubMed ID: 23488279
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacotherapy of urticaria--an analysis of the discrepancies between guidelines of expert bodies, registration documents and evidence for the effectiveness of drugs].
Plichta D; Spiewak R
Przegl Lek; 2013; 70(12):1015-20. PubMed ID: 24720119
[TBL] [Abstract][Full Text] [Related]
4. [Physician versus 'off-label" ordinance].
Kordus K; Spiewak R
Przegl Lek; 2015; 72(1):38-41. PubMed ID: 26076577
[TBL] [Abstract][Full Text] [Related]
5. What is new in atopic dermatitis/eczema?
Plötz SG; Wiesender M; Todorova A; Ring J
Expert Opin Emerg Drugs; 2014 Dec; 19(4):441-58. PubMed ID: 25286776
[TBL] [Abstract][Full Text] [Related]
6. [Health services research the example of atopic dermatitis].
Schmitt J
Hautarzt; 2011 Mar; 62(3):178-88. PubMed ID: 21340649
[TBL] [Abstract][Full Text] [Related]
7. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II.
Wollenberg A; Barbarot S; Bieber T; Christen-Zaech S; Deleuran M; Fink-Wagner A; Gieler U; Girolomoni G; Lau S; Muraro A; Czarnecka-Operacz M; Schäfer T; Schmid-Grendelmeier P; Simon D; Szalai Z; Szepietowski JC; Taïeb A; Torrelo A; Werfel T; Ring J;
J Eur Acad Dermatol Venereol; 2018 Jun; 32(6):850-878. PubMed ID: 29878606
[TBL] [Abstract][Full Text] [Related]
8. Systemic treatment of severe atopic eczema: a systematic review.
Schmitt J; Schäkel K; Schmitt N; Meurer M
Acta Derm Venereol; 2007; 87(2):100-11. PubMed ID: 17340015
[TBL] [Abstract][Full Text] [Related]
9. What's new in atopic eczema? An analysis of systematic reviews published in 2018. Part 2: systemic therapies.
Olabi B; Worboys S; Garland T; Grindlay DJC; Rogers NK; Harman KE
Clin Exp Dermatol; 2020 Dec; 45(8):980-985. PubMed ID: 32568435
[TBL] [Abstract][Full Text] [Related]
10. Low dose methotrexate therapy is effective in late-onset atopic dermatitis and idiopathic eczema.
Zoller L; Ramon M; Bergman R
Isr Med Assoc J; 2008 Jun; 10(6):413-4. PubMed ID: 18669134
[TBL] [Abstract][Full Text] [Related]
11. [Therapy of atopic eczema with calcineurin inhibitors].
Luger TA; Bieber T; Meurer M; Mrowietz U; Schwarz T; Simon J; Werfel T; Zuberbier T
J Dtsch Dermatol Ges; 2005 May; 3(5):385-91. PubMed ID: 16372807
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review.
Roekevisch E; Spuls PI; Kuester D; Limpens J; Schmitt J
J Allergy Clin Immunol; 2014 Feb; 133(2):429-38. PubMed ID: 24269258
[TBL] [Abstract][Full Text] [Related]
13. A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema.
Pitt M; Garside R; Stein K
Br J Dermatol; 2006 Jun; 154(6):1137-46. PubMed ID: 16704646
[TBL] [Abstract][Full Text] [Related]
14. What's new in atopic eczema? An analysis of the clinical significance of systematic reviews on atopic eczema published in 2006 and 2007.
Williams HC; Grindlay DJ
Clin Exp Dermatol; 2008 Nov; 33(6):685-8. PubMed ID: 18691244
[TBL] [Abstract][Full Text] [Related]
15. The European TREatment of severe Atopic eczema in children Taskforce (TREAT) survey.
Proudfoot LE; Powell AM; Ayis S; Barbarot S; Baselga Torres E; Deleuran M; Fölster-Holst R; Gelmetti C; Hernández-Martin A; Middelkamp-Hup MA; Oranje AP; Logan K; Perkin M; Patrizi A; Rovatti G; Schofield O; Spuls P; Svensson Å; Vestergaard C; Wahlgren CF; Schmitt J; Flohr C;
Br J Dermatol; 2013 Oct; 169(4):901-9. PubMed ID: 23855450
[TBL] [Abstract][Full Text] [Related]
16. Guidelines for treatment of atopic eczema (atopic dermatitis) part I.
Ring J; Alomar A; Bieber T; Deleuran M; Fink-Wagner A; Gelmetti C; Gieler U; Lipozencic J; Luger T; Oranje AP; Schäfer T; Schwennesen T; Seidenari S; Simon D; Ständer S; Stingl G; Szalai S; Szepietowski JC; Taïeb A; Werfel T; Wollenberg A; Darsow U; ; ; ; ; ;
J Eur Acad Dermatol Venereol; 2012 Aug; 26(8):1045-60. PubMed ID: 22805051
[TBL] [Abstract][Full Text] [Related]
17. [Diagnostic, prophylactic and therapeutic guidelines in patients with atopic dermatitis. Position paper by the task force of the National Specialists on Dermatology, Venereology and Allergology].
Gliński W; Kruszewski J; Silny W; Kurzawa R; Czarnecka-Operacz M; Baran E; Szepietowski J;
Pol Merkur Lekarski; 2004; 17 Suppl 3():3-15. PubMed ID: 15688665
[TBL] [Abstract][Full Text] [Related]
18. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II.
Ring J; Alomar A; Bieber T; Deleuran M; Fink-Wagner A; Gelmetti C; Gieler U; Lipozencic J; Luger T; Oranje AP; Schäfer T; Schwennesen T; Seidenari S; Simon D; Ständer S; Stingl G; Szalai S; Szepietowski JC; Taïeb A; Werfel T; Wollenberg A; Darsow U; ; ; ; ; ;
J Eur Acad Dermatol Venereol; 2012 Sep; 26(9):1176-93. PubMed ID: 22813359
[TBL] [Abstract][Full Text] [Related]
19. [Off-label use and G-BA. Legal framework for off-label use].
Brucklacher U; Brockmeyer NH; Riedel C
Hautarzt; 2013 Oct; 64(10):736-42. PubMed ID: 24150821
[TBL] [Abstract][Full Text] [Related]
20. Management of atopic dermatitis: nonadherence to topical therapies in treatment of skin disease and the use of calcineurin inhibitors in difficult eczema.
Anstey A
Br J Dermatol; 2009 Aug; 161(2):219-20. PubMed ID: 19664122
[No Abstract] [Full Text] [Related]
[Next] [New Search]
